Drugs in the Pipeline, News
Rilzabrutinib Fails in Phase 3 Pemphigus Trial
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Your search for oral corticosteroids returned 8 results
Drugs in the Pipeline
Tezepelumab BLA Submitted for Severe Asthma
The BLA submission is supported by data from the PATHFINDER clinical program.
Drugs in the Pipeline
Dupilumab Under Review for Pediatric Asthma
The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
Drugs in the Pipeline
Phase 3 Study of ACZ885 for Children with Systemic Juvenile Idiopathic Arthritis
Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).
Drugs in the Pipeline
Phase 3 Study of Uceris for Ulcerative Colitis
Santarus announced pooled data from two Phase 3 studies of Uceris (budesonide MMX) for the induction of remission of mild or moderate active ulcerative colitis.
Drugs in the Pipeline
Phase 3 Study of Masitinib for the Treatment of Asthma
AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.
Drugs in the Pipeline
Supplemental NDA submitted for Aerospan for asthma
Acton announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for its new asthma product, Aerospan (flunisolide HFA, 80 mcg) Inhalation Aerosol.
Drugs in the Pipeline
Phase 3 study of LX211 (Luveniq) for uveitis
Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company's LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.
